Insurance coverage for GLP-1 medications is limited and inconsistent. Most commercial plans don't cover them for weight loss, Medicare excludes them entirely, and the coverage that does exist comes with prior authorization hurdles. Here's the honest picture.
Commercial Insurance
For type 2 diabetes: Coverage is more common. Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for T2D and appear on many commercial formularies. Step therapy requirements, quantity limits, and prior authorization are common, but coverage is achievable.
For weight loss: Coverage is rare. The majority of commercial insurance plans exclude GLP-1 medications for the obesity indication. Some employer-sponsored plans have added coverage under pressure from employees, but this is the exception, not the rule.
Check your plan's formulary directly. If you have T2D, request prescriptions under that indication where clinically appropriate, the medications are the same, only the indication differs.
Medicare
Medicare Part D explicitly excludes weight loss medications from coverage. This is a statutory exclusion written into law (though there are ongoing legislative efforts to change it). Medicare does cover GLP-1 medications for type 2 diabetes (under Part D) and for cardiovascular risk reduction (Wegovy received approval for this indication, which may affect Medicare coverage).
Medicaid
Medicaid coverage varies significantly by state. Some state programs cover GLP-1 medications for obesity; most don't. Check your specific state's Medicaid formulary.
Prior Authorization Reality
Even when insurance technically covers GLP-1 medications, prior authorization requirements create significant barriers. Typical requirements include:
- Documentation of qualifying BMI
- Evidence of prior weight loss attempts (often including dietary programs)
- Absence of contraindications
- Physician letter of medical necessity
Prior authorization denials are common, and appeals take time. Many patients who have coverage in theory wait months to receive medication.
The Practical Reality: Compounded Medication
For most people without T2D who want GLP-1 medications for weight loss, compounded semaglutide or tirzepatide through a telehealth provider at $147–280/month is the practical access pathway, not insurance. This bypasses the prior authorization process entirely and typically results in medication delivery within one week.